To receive the full Confidential Information Memorandum and financial details, please execute the Non-Disclosure Agreement, copy and paste link below into your web browser.

https://app.boldsign.com/document/sign-bulk-links/?documentId=c4794836-18e2-43ce-b2d8-8a0559a8dd3as_iKIex

BUSINESS DESCRIPTION

Offered exclusively through The Raivax Group, this is a rare opportunity to acquire a premier, fully operational private clinical research center with over 55 years of continuous operating history and one of the strongest regulatory track records in the industry.
Founded in 1969 and headquartered in Ohio, the Center has completed 900+ Phase II–IV clinical trials across adult and pediatric populations, serving as a trusted long-term research partner to 25+ leading pharmaceutical, biotech, and CRO sponsors. The business operates as a dedicated, stand-alone research site purpose-built for clinical trial execution.

Operations

The Center operates through a centralized coordinator-led model in which a highly trained, cross-functional team manages the full research cycle end-to-end — from patient recruitment and informed consent through dosing, safety monitoring, data capture, and regulatory close-out. This model drives operational efficiency, sponsor confidence, and consistently high data quality without reliance on any single individual.

The facility is fully equipped with an on-site laboratory, specialized clinical infrastructure, and secured monitored drug supply management. Advanced Electronic Data Capture systems with custom-built source documents enable rapid query resolution and real-time reporting to sponsors. Robust SOPs are in place across all study functions.

Team

The core clinical team averages 28+ years of industry tenure, with coordinators cross-trained across all study functions. This depth of experience ensures operational continuity through any ownership transition. Two board-certified Principal Investigators with decades of tenure lead the research program. Management is committed to supporting a 1–2 year transition period to ensure a seamless handover of all sponsor relationships, regulatory processes, and ongoing studies.
Financial Performance

The Center has delivered consistent revenue between $1.18M and $1.52M over the past four years, supported by a diversified portfolio of sponsor relationships and a stable patient base. Historical EBITDA margins ranged 30–36% from 2022–2024, with 2025 at 27% reflecting short-term study timing rather than a structural decline - presenting a clear opportunity for margin recovery under new ownership. The balance sheet is clean with zero long-term liabilities.

2025 Gross Revenue: $1.2M
3-Year Average Revenue (2023–2025): $1.4M
2025 Adjusted EBITDA: $300K
2025 EBITDA Margin: 26%
2022–2024 Average EBITDA: ~$505K


Growth Opportunities

A new owner is well-positioned to accelerate growth through several identified levers:

-Expand into adjacent high-demand therapeutic areas to diversify the study portfolio
-Target emerging biologics and gene therapy trials to capture high-value complex studies
-Increase study throughput by approximately 25% through strategic coordinator hiring
-Invest in digital infrastructure to enhance data capture, compliance, and sponsor reporting
-Leverage existing sponsor relationships to attract new CRO partnerships and trial volume
-Enhance digital marketing presence and visibility on major study listing platforms to attract new sponsors